Wedbush Boosts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target boosted by Wedbush from $38.00 to $41.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2027 earnings at $4.88 EPS and FY2028 earnings at $5.61 EPS.

Several other equities analysts also recently issued reports on APLS. Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an equal weight rating on the stock in a report on Thursday, May 23rd. HC Wainwright decreased their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a buy rating for the company in a report on Friday, August 2nd. Robert W. Baird boosted their price objective on shares of Apellis Pharmaceuticals from $86.00 to $96.00 and gave the company an outperform rating in a report on Friday. UBS Group reduced their target price on Apellis Pharmaceuticals from $89.00 to $85.00 and set a buy rating for the company in a research note on Wednesday, May 8th. Finally, Citigroup dropped their price target on Apellis Pharmaceuticals from $67.00 to $60.00 and set a buy rating on the stock in a research note on Wednesday, May 8th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $72.63.

Apellis Pharmaceuticals Price Performance

NASDAQ APLS opened at $36.16 on Friday. The firm’s fifty day simple moving average is $38.62 and its two-hundred day simple moving average is $49.27. The firm has a market capitalization of $4.39 billion, a P/E ratio of -10.45 and a beta of 0.88. The company has a current ratio of 5.08, a quick ratio of 3.02 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals has a 12-month low of $29.79 and a 12-month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. During the same quarter last year, the firm earned ($1.02) EPS. The business’s quarterly revenue was up 110.2% on a year-over-year basis. Analysts forecast that Apellis Pharmaceuticals will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the sale, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 6.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Sippican Capital Advisors raised its stake in shares of Apellis Pharmaceuticals by 1.1% during the 4th quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock worth $958,000 after buying an additional 170 shares during the period. Amalgamated Bank increased its holdings in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares in the last quarter. Simplicity Wealth LLC raised its position in Apellis Pharmaceuticals by 0.6% during the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock worth $3,021,000 after acquiring an additional 499 shares during the period. Future Financial Wealth Managment LLC purchased a new position in Apellis Pharmaceuticals during the first quarter valued at $29,000. Finally, Oppenheimer Asset Management Inc. grew its position in shares of Apellis Pharmaceuticals by 8.3% in the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock valued at $511,000 after purchasing an additional 664 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).